1-156137204-G-C
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_170707.4(LMNA):c.1580G>C(p.Arg527Pro) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R527C) has been classified as Likely pathogenic.
Frequency
Consequence
NM_170707.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LMNA | NM_170707.4 | c.1580G>C | p.Arg527Pro | missense_variant | Exon 9 of 12 | ENST00000368300.9 | NP_733821.1 | |
LMNA | NM_005572.4 | c.1580G>C | p.Arg527Pro | missense_variant | Exon 9 of 10 | ENST00000677389.1 | NP_005563.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LMNA | ENST00000368300.9 | c.1580G>C | p.Arg527Pro | missense_variant | Exon 9 of 12 | 1 | NM_170707.4 | ENSP00000357283.4 | ||
LMNA | ENST00000677389.1 | c.1580G>C | p.Arg527Pro | missense_variant | Exon 9 of 10 | NM_005572.4 | ENSP00000503633.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial partial lipodystrophy, Dunnigan type Pathogenic:2
- -
The LMNA c.1580G>C(p.Arg527Pro) variant has been reported in individuals affected with lipodystrophy (Kooi et al., 2002). Experimental studies have shown that an abnormal phenotype was seen in transfected cells with the R527P variant: nuclear aggregates of lamin A and displacement to cytoplasmic aggregates. This variant has been reported to affect LMNA protein function (Motsch et al., 2005). The p.Arg527Pro variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. It has been submitted to ClinVar with varying interpretations: Pathogenic. The variant affects a highly conserved arginine residue. This sequence change replaces arginine with proline at codon 527 of the LMNA protein (p.Arg527Pro) and it might alter its composition and physico-chemical properties. The variant is predicted to be damaging by both SIFT and PolyPhen2. The residue is conserved across species. The amino acid change p.Arg527Pro in LMNA is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. -
Charcot-Marie-Tooth disease type 2 Pathogenic:1
This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 527 of the LMNA protein (p.Arg527Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant muscular dystrophies (PMID: 10080180, 19084400, 20980393). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 14481). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt LMNA protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects LMNA function (PMID: 16218190, 19933576). This variant disrupts the p.Arg527 amino acid residue in LMNA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12075506, 14627682, 18604166, 19432833, 23497705, 25286833, 25324471, 25823658). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Primary dilated cardiomyopathy Pathogenic:1
This sequence change results in a missense variant in the LMNA gene (p.(Arg527Pro)). (PP2; based on GnomAd constraint matrix). This variant is absent from population databases such as GnomAD (PM2) . This variant has been described in literature (PMID: 16218190; PMID: 19933576) (PP1). An abnormal phenotype was seen in transfected cells with the R527P variant: nuclear aggregates of lamin A and displacement to cytoplasmic aggregates. Of the different LMNA variants studied in this paper, R527P produced the most severe phenotype on cellular level (PMID: 19933576) (PS3). The variant has been described in several individuals and families affected with AD muscular dystrophies and segregated with the disease in these families (PMID: 10080180, 19084400, 20980393).The variant affects a highly conserved amino acid. Other variants that disrupt this amino acid have been reported as pathogenic p.Arg527His (PMID: 12075506, 14627682, 18604166, 25823658, 25324471) and p.Arg527Cys (PMID:19432833, 23497705, 25286833) (PM5). We identified this variant in a patients with DCM. In conclusion this variant was classified as pathogenic according to ACMG-guidelines (PS3, PM2,PM5,PP1,PP2). -
Cardiovascular phenotype Pathogenic:1
The p.R527P pathogenic mutation (also known as c.1580G>C), located in coding exon 9 of the LMNA gene, results from a G to C substitution at nucleotide position 1580. The arginine at codon 527 is replaced by proline, an amino acid with dissimilar properties. This alteration has been reported in numerous individuals with laminopathies, including muscular dystrophies, and segregated with disease in some families (Bonne G et al. Nat Genet, 1999 Mar;21:285-8; van der Kooi AJ et al. Neurology, 2002 Aug;59:620-3; Mitsuhashi H et al. J Cell Sci, 2010 Nov;123:3893-900; van Rijsingen IA et al. Eur J Heart Fail, 2013 Apr;15:376-84; Tan D et al. PLoS One, 2015 Jun;10:e0129699; Ben Yaou R et al. Brain Commun, 2021 Jul;3:fcab075; Fan Y et al. J Med Genet, 2021 May;58:326-333; Vasandani C et al. J Endocr Soc, 2022 Oct;6:bvac155). Additionally, this alteration was detected as de novo in two siblings with muscular dystrophy (Makri S et al. Neuromuscul Disord, 2009 Jan;19:26-8). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is predicted to be deleterious by BayesDel in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Emery-Dreifuss muscular dystrophy 2, autosomal dominant Pathogenic:1
- -
not provided Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at